Figure 1. Mortality in patients according to sinus rhythm and triple therapy [angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), beta-blocker and mineralocorticoid receptor antagonist (MRA)] by type 2 diabetes mellitus group.
